Instrumento Inactivo

Otros idiomas Curis, Inc. Nasdaq

Acciones

Curis Announces Additional Data from TakeAim Leukemia Study	14/05
Curis to Present Updated Data from the TakeAim Leukemia Study	13/05
Curis to Present Updated Data from the TakeAim Leukemia Study	10/05
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M	07/05
Curis: Q1 Earnings Snapshot	07/05
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024	30/04
Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	08/04
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Curis to Present at Upcoming Healthcare Conferences in April	04/04
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)	02/04
Curis Provides Fourth Quarter 2023 Business Update	09/02
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Curis: Q4 Earnings Snapshot	08/02
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M	08/02
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024	01/02
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/01
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study	12/12
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	12/12

No hay resultados para esta búsqueda